Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine

Vaccines

Jeanne Galaine¹  Christophe Borg¹  Yann Godet¹  Olivier Adotévi¹ 

[1]INSERM UMR1098, Besançon cedex F25020, France

[2] E-Mails:

关键词: CD4 T cell;    tumor antigen;    helper peptide;    cancer vaccine;   

DOI  :  10.3390/vaccines3030490

来源: mdpi

【 摘 要 】

Nowadays, immunotherapy represents one promising approach for cancer treatment. Recently, spectacular results of cancer immunotherapy clinical trials have confirmed the crucial role of immune system in cancer regression. Therapeutic cancer vaccine represents one widely used immunotherapy strategy to stimulate tumor specific T cell responses but clinical impact remains disappointing in targeting CD8 T cells. Although CD8 T cells have been initially considered to be the main protagonists, it is now clear that CD4 T cells also play a critical role in antitumor response. In this article, we discuss the role of tumor antigen-specific CD4 T cell responses and how we can target these cells to improve cancer vaccines.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.